ReSync Bio Launches to Automate Data and Operations in Drug Discovery

ReSync Bio Launches to Automate Data and Operations in Drug Discovery

By, Admin 27 September 2024

Overview

ReSync Bio, a scientific software provider accelerating preclinical R&D, today announced the company’s launch and a fundraise from Caffeinated Capital, Atria Ventures and leading angel investors including Ramsey Homsany, co-founder of Octant Bio. The company will use the funds to make key hires and commercialize their platform, which is now available for use by companies and academics.

Present Condition of Preclinical Drug Discovery

  • Preclinical drug discovery today is slowed by numerous bottlenecks. 
  • Disconnected software tools make it difficult to coordinate data across various computational models, in-house labs, and contract research organizations (CROs). 
  • Disorganized and siloed data makes adopting modern AI tooling difficult. 
  • This forces pharmaceutical and biotechnology companies to keep reinventing the data engineering wheel with bespoke solutions that take time and resources away from their science.

Statement from the Founder & CEO: ReSync

  • Our mission is to accelerate drug discovery programs across the industry,” said ReSync Founder and CEO Mihir Trivedi. 
  • AI advances in generative drug discovery have transformed throughput on the digital side, but major challenges remain in translating this progress to the experimental side of the life sciences, where it takes far too long to go from idea to assay data. ReSync is a bridge that synergizes the digital and experimental worlds to help bring therapeutics to the clinic faster.

Objectives of ReSync

  • ReSync was inspired by Trivedi’s tenure as an early engineer at PostEra, where he saw firsthand the need for more standard tooling in AI-driven drug discovery. 
  • ReSync’s platform is designed to help companies organize and train their data, models, and experimental workflows more efficiently.

Statement from Atria Ventures

  • The reality in the lab today is that AI drug discovery programs are hindered by uncoordinated experiments and unstructured data,” said Chris Leiter of Atria Ventures. 
  • ReSync is a universal tool that any life sciences company can use to eliminate preclinical bottlenecks and make their data work smarter. ReSync is the essential automation layer of the life sciences that makes AI bioacceleration possible.”

About the ReSync’s platform

  • ReSync’s platform automates coordination between drug discovery teams and their labs - whether they be in-house or external CROs. 
  • The software includes tightly controlled permissioning that lets companies control data access and promote collaboration while protecting IP.

Statement from Caffeinated Capital

  • Companies like Microsoft and NVIDIA are investing billions in AI-powered drug discovery platforms and services, but there’s still a huge unmet need for better data infrastructure to realize the potential of these technologies,” said Varun Gupta of Caffeinated Capital. 
  • We believe ReSync can become a keystone of the AI drug discovery space that enables hundreds of other companies to bring lifesaving therapeutics to market.

From ReSync

ReSync’s goal is to make therapeutics companies more efficient, so they make decisions faster and ultimately bring therapies to the clinic – and patients – quickly,” added Trivedi.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!